You Can Help
Contact
Forum
Shop
Search
Sign Up
Donate
You Can Help
What is ALS
Newly Diagnosed?
Treatments & ALS Drugs
Frequently Asked Questions
Glossary
ALS Research
Drug Discovery Engine
ALS Research Collaborative
ARC Data Commons
Research News
Meet Our Scientists
Translational Research
Explore Our Lab
Publications
Help Fund Treatments
Donate
Start a Fundraiser
Events
ALS Awareness
Other Ways to Give
Corporate Opportunities
Resources
ALS Forum
ALS Clinical Trials
News
ALS Town Hall
ALS TDI Community Conversations
ALS Unfiltered
Podcasts
About Us
History
Team
Our Supporters
Schedule a Tour
Financials
Press Room
Contact Us
You Can Help
Contact
Forum
Search
Donate
Sign Up
Your support fuels our research to #EndALS!
Donate Now
ALS Clinical Trials
RAPA-501 Therapy for ALS
ALS Clinical Trials
RAPA-501 Therapy for ALS
Quick Info
Status
Recruiting
Phase
2/3
Trial Type
Biological
Treatment Type
RAPA-501 Autologous T cells
Randomization
Open label
Enrollment
41
Start Date
12/15/2020
Sponsor
Rapa Therapeutics LLC
Contact Information
Jennifer Gough Clinical Regulatory Coordinator 617
jgough@rapatherapeutics.com
Locations
United States, Massachusetts
Massachusetts General Hospital, Boston, MA, 02114, United States
Contact: Jacqueline Topping  
617-643-6036
 
JTOPPING@mgh.harvard.edu
United States, New Jersey
Hackensack University Medical Center, Hackensack, NJ, 07601, United States
Contact: Michele Donato Principal Investigator  
551-996-5855
 
michele.donato@hackensackmeridian.org
Enrollment Criteria
Breathing Ability
Percent lung function (
FVC
) or (
SVC
)
≥ 50%
Months Since Onset
Number of months since first symptoms of ALS.
N/A
Non-Invasive Ventilation (NIV)
Can PALS use a BiPAP in the trial?
N/A
Diaphragm Pacer (DPS)
Can PALS use a
DPS
in the trial?
N/A
Edaravone Usage
Can a PALS use edaravone (Radicut/Radicava) while enrolled in the trial?
No
Open Label
No
Update Notes
Trial has now switched to phase 2/3 expansion study.
5/3/2023
Protocol updates
3/17/2022
Primary contact updated
11/2/2021
Site contact updated
7/29/2021
Protocol updates
7/2/2021
Site contact updates
4/28/2021
New sites recruiting
4/12/2021
Study recruited, criteria updated
1/13/2021
Site contact updated
11/20/2020
No significant updates
9/21/2020
No significant updates
7/22/2020
No significant updates.
6/25/2020
New Trial Added
1/7/2020
Other Information
Purpose
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
Eligibility
Inclusion Criteria:
1. Male or female patients ≥ 18 years of age.
2. Patients with sporadic or familial amyotrophic lateral sclerosis (ALS) diagnosed as laboratory-supported possible, probable, or definite according to World Federation of Neurology El Escorial Criteria.
3. . Less than or equal to 24 months since ALS symptom onset.
4. Total ALSFRS-R score between 34 and 45.
5. Must have a source of autologous T cells potentially sufficient to manufacture RAPA-501 cells, as defined by a peripheral CD3+ T cell count ≥ 500 cells per μl.
6. Patients may continue riluzole (Rilutek®), and/or edaravone (Radicava®), and/or sodium phenylbutyrate/taurusodial (Relyvrio™) if on a stable dose for at least 30 days prior to the screening visit.
7. Patients must be ≥ 2 two weeks removed from major surgery or investigational therapy.
8. Patients must have recovered from clinical toxicities ([resolution of CTCAE(v5) [version 5] toxicity to a value of ≤ 2].).
9. Serum creatinine ≤ less than or equal to 2.0 mg/dL.
10. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN).
11. Bilirubin ≤ 1.5 (except if due to Gilbert's disease).
12. Pulmonary slow vital capacity (SVC) ≥ 70% of predicted normal.
13. No history of abnormal bleeding tendency.
14. Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient participant at any time without prejudice to future medical care.
Exclusion Criteria:
1. Active uncontrolled infection.
2. Hypertension not adequately controlled by ≤ 3 medications.
3. History of documented pulmonary embolus within 6 months of enrollment.
4. Clinically significant cardiac pathology, as defined by: myocardial infarction within 6 months prior to enrollment, Class III or IV heart failure according to NYHA, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
5. Patients with history of coronary artery bypass grafting or angioplasty will receive a cardiology evaluation and be considered on a case-by-case basis.
6. HIV, hepatitis B, or hepatitis C seropositive.
7. Pregnancy or breastfeeding patients.
8. Patients of Subjects of childbearing age, or males who have a partner of childbearing potential, who are unwilling to practice contraception.
9. Patients Subjects may be excluded at the Principal Investigator discretion of the PI or if it is deemed that allowing participation would represent an unacceptable medical or psychiatric risk.
Details
This is an open-label, non-randomized, multi-center phase 2/3 study evaluating RAPA-501 T cell therapy in pwALS on an expansion cohort. After a subject consents to the study, an apheresis procedure will be performed to collect cells to manufacture the investigational product, RAPA-501 T cells. RAPA-501 cells are manufactured ex vivo using epigenetic reprogramming to yield a T cell population that is enriched for a dual anti-inflammatory phenotype based on hybrid TREG and Th2 differentiation. RAPA-501 cells express both the TREG and Th2 transcription factors FOXP3 and GATA3, are enriched for expression of the ATP ectonucleotidase molecules CD39 and CD73, are enriched for the T cell homing molecule CD103, and suppress both effector T cell inflammatory molecules and CNS microglial cell inflammatory molecules. This study consists of a phase 2/3 expansion cohort that is evaluating RAPA-501 T cell therapy at the dose of 80 x 10EE6 cells per infusion, with up to 4 infusions separated by six weeks between doses (infusion at time 0, and then after week 6, 12, and 18). Study subjects are then followed at the treatment site at 24 weeks and 30 weeks on-study; then, subjects are followed remotely using surveys for two years to capture major clinical events and assess survival. The primary objective in the expansion cohort is to determine the feasibility and safety of the highest established safe dose of RAPA-501 (80 x 10EE6 cells per infusion) in patients with standard-risk ALS (as defining by study entry values of: SVC greater than or equal to 70% of predicted normal; time interval since first ALS symptom, 24 months or less; and ALSFRS-R score between 34 and 45). Secondary study objectives relate to assessing the potential efficacy of RAPA-501 therapy through monitoring of ALSFRS-R scores, SVC values, time to King's stage transition, and survival. To enhance an ability to determine potential efficacy, these parameters will be compared to two comparator arms using machine learning algorithms developed by Origent Data Sciences, namely: (1) a virtual intra-patient control cohort (patient serves as own control); and (2) a comparator arm developed by prognostic mapping to the PRO-ACT database. In addition, secondary study objectives relate to study of pre- and post-therapy blood samples (serum and cells) for markers of inflammation and neurodegeneration. In the initial phase 1/2 study design, patients received therapy on Cohort 1 (low-dose RAPA-501; 20 x 10EE6 cells per infusion), Cohort 2 (high-dose RAPA-501; 80 x 10EE6 cells per infusion), and Cohort 3A (low-dose RAPA-501 when administered after a 3-day host conditioning regimen consisting of pentostatin plus cyclophosphamide. At the time of study amendment to add the expansion cohort, some patients already enrolled to the phase 1/2 aspect of the trial will continue to receive their initially designated cohort therapy and follow-up evaluation.
Collaborator(s)
Rapa Therapeutics LLC
Hackensack Meridian Health
Trial Protocol as Published on Clinicaltrials.gov
NCT04220190
(First Published: 1/3/2020)
What is ALS
ALS Research
Help Fund Treatments
Resources
About Us
Contact
Forum
Shop
Search
Donate
Sign Up
What is ALS
Overview
Newly Diagnosed?
Treatments & ALS Drugs
FAQS
Glossary
Contact
Forum
Shop
Search
Donate
Sign Up
ALS Research
Overview
Drug Discovery Engine
ALS Research Collaborative
ARC Data Commons
Research News
Meet Our Scientists
Translational Research
Explore Our Lab
Publications
Contact
Forum
Shop
Search
Donate
Sign Up
Help Fund Treatments
Overview
Donate
Start a Fundraiser
Events
ALS Awareness
Other Ways To Give
Corporate Opportunities
Contact
Forum
Shop
Search
Donate
Sign Up
Resources
Overview
ALS Forum
ALS Clinical Trials
News
ALS Town Hall
ALS TDI Community Conversations
ALS Unfiltered
Podcasts
Contact
Forum
Shop
Search
Donate
Sign Up
About Us
Overview
History
Team
Our Supporters
Schedule a Tour
Financials
Press Room
Contact Us
Contact
Forum
Shop
Search
Donate
Sign Up
Cookie Declaration
×
ALS is not
incurable.
Your donation
today could help
lead to cures.
Make an impact
ALS is not incurable.
Your donation today could help lead to cures.
Make an impact